AKT1 and neoplasm: As seen in Figure 5B, GSK2879552 treatment significantly decreased AKT phosphorylation, suggesting that the impairment of PI3K/AKT signaling may be one mechanism contributing to the tumor regression effect by LSD1 inhibition.